The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
The term of O&M is for 15 years with a lock in period of 5 years for the Company and 15 years for VHPL & Bharathi Education trust.
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.
Subscribe To Our Newsletter & Stay Updated
